Shopping Cart 0
Cart Subtotal
AED 0

MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

MEI Pharma Inc (MEIP)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MEI Pharma Inc (MEI Pharma), formerly Marshall Edwards Inc, develops drugs for the treatment of cancer. The company's drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including acute myeloid leukemia and myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies, refractory chronic lymphocytic leukemia and follicular lymphoma. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor through agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.

MEI Pharma Inc Key Recent Developments

Nov 01,2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting

Aug 30,2018: MEI Pharma reports fiscal year 2018 results and operational highlights

Aug 29,2018: MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference

Jul 16,2018: MEI Pharma announces promotion of David M. Urso to chief operating officer

May 14,2018: MEI Pharma Announces USD 75 Million Private Placement

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

MEI Pharma Inc-Key Facts 6

MEI Pharma Inc-Key Employees 7

MEI Pharma Inc-Key Employee Biographies 8

MEI Pharma Inc-Major Products and Services 9

MEI Pharma Inc-History 10

MEI Pharma Inc-Company Statement 11

MEI Pharma Inc-Locations And Subsidiaries 12

Head Office 12

Section 2-Company Analysis 13

Company Overview 13

MEI Pharma Inc-Business Description 14

MEI Pharma Inc-Corporate Strategy 15

MEI Pharma Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

MEI Pharma Inc-Strengths 16

MEI Pharma Inc-Weaknesses 17

MEI Pharma Inc-Opportunities 18

MEI Pharma Inc-Threats 19

MEI Pharma Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

MEI Pharma Inc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Nov 01, 2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting 31

Aug 30, 2018: MEI Pharma reports fiscal year 2018 results and operational highlights 35

May 14, 2018: MEI Pharma Announces USD 75 Million Private Placement 37

May 09, 2018: MEI Pharma Reports Third Quarter Fiscal Year 2018 Results 38

Feb 08, 2018: MEI Pharma Reports Second Quarter Fiscal Year 2018 Results 40

Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 42

Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 43

May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 45

Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 46

Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 47

Section 6-Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

MEI Pharma Inc, Performance Chart (2014-2018) 25

MEI Pharma Inc, Ratio Charts 27

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29


List Of Table

List of Tables

MEI Pharma Inc, Key Facts 6

MEI Pharma Inc, Key Employees 7

MEI Pharma Inc, Key Employee Biographies 8

MEI Pharma Inc, Major Products and Services 9

MEI Pharma Inc, History 10

MEI Pharma Inc, Key Competitors 20

MEI Pharma Inc, Ratios based on current share price 21

MEI Pharma Inc, Annual Ratios 22

MEI Pharma Inc, Annual Ratios (Cont...1) 23

MEI Pharma Inc, Annual Ratios (Cont...2) 24

MEI Pharma Inc, Interim Ratios 26

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

MEI Pharma Inc, Recent Deals Summary 30

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MEI Pharma Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

ZIOPHARM Oncology Inc

Verastem Inc

Onconova Therapeutics Inc

Cleveland BioLabs Inc

Cellectar Biosciences Inc

MEI Pharma Inc (MEIP)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MEI Pharma Inc (MEI Pharma), formerly Marshall Edwards Inc, develops drugs for the treatment of cancer. The company's drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including acute myeloid leukemia and myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies, refractory chronic lymphocytic leukemia and follicular lymphoma. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor through agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.

MEI Pharma Inc Key Recent Developments

Nov 01,2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting

Aug 30,2018: MEI Pharma reports fiscal year 2018 results and operational highlights

Aug 29,2018: MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference

Jul 16,2018: MEI Pharma announces promotion of David M. Urso to chief operating officer

May 14,2018: MEI Pharma Announces USD 75 Million Private Placement

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

MEI Pharma Inc-Key Facts 6

MEI Pharma Inc-Key Employees 7

MEI Pharma Inc-Key Employee Biographies 8

MEI Pharma Inc-Major Products and Services 9

MEI Pharma Inc-History 10

MEI Pharma Inc-Company Statement 11

MEI Pharma Inc-Locations And Subsidiaries 12

Head Office 12

Section 2-Company Analysis 13

Company Overview 13

MEI Pharma Inc-Business Description 14

MEI Pharma Inc-Corporate Strategy 15

MEI Pharma Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

MEI Pharma Inc-Strengths 16

MEI Pharma Inc-Weaknesses 17

MEI Pharma Inc-Opportunities 18

MEI Pharma Inc-Threats 19

MEI Pharma Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

MEI Pharma Inc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Nov 01, 2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting 31

Aug 30, 2018: MEI Pharma reports fiscal year 2018 results and operational highlights 35

May 14, 2018: MEI Pharma Announces USD 75 Million Private Placement 37

May 09, 2018: MEI Pharma Reports Third Quarter Fiscal Year 2018 Results 38

Feb 08, 2018: MEI Pharma Reports Second Quarter Fiscal Year 2018 Results 40

Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 42

Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 43

May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 45

Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 46

Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 47

Section 6-Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

MEI Pharma Inc, Performance Chart (2014-2018) 25

MEI Pharma Inc, Ratio Charts 27

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29


List Of Table

List of Tables

MEI Pharma Inc, Key Facts 6

MEI Pharma Inc, Key Employees 7

MEI Pharma Inc, Key Employee Biographies 8

MEI Pharma Inc, Major Products and Services 9

MEI Pharma Inc, History 10

MEI Pharma Inc, Key Competitors 20

MEI Pharma Inc, Ratios based on current share price 21

MEI Pharma Inc, Annual Ratios 22

MEI Pharma Inc, Annual Ratios (Cont...1) 23

MEI Pharma Inc, Annual Ratios (Cont...2) 24

MEI Pharma Inc, Interim Ratios 26

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

MEI Pharma Inc, Recent Deals Summary 30

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MEI Pharma Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

ZIOPHARM Oncology Inc

Verastem Inc

Onconova Therapeutics Inc

Cleveland BioLabs Inc

Cellectar Biosciences Inc